Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-12-02T21:53:23.963Z Has data issue: false hasContentIssue false

What is the genetic architecture of major psychiatric disorders?

Published online by Cambridge University Press:  13 August 2021

W. Hennah*
Affiliation:
Neuroscience Center, University of Helsinki, Helsinki, Finland
M. Gennarelli
Affiliation:
Department Of Molecular And Translational Medicine, University of Brescia, Brescia, Italy
*
*Corresponding Author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Taken as a whole, psychiatric disorders are considered as complex genetic disorders. There are clear genetic mutations and susceptibility factors to these disorders. However, these form the full spectrum of impact, frequency, and mutation type. With rare large scale chromosomal rearrangements and copy number mutations of high impact at one end, and common single nucleotide variations of minor impact at the other. This multitude of variation type also means that different epidemiological study designs are needed to test the genetic component of these disorders, from familial forms, to common population level studies. This process has been facilitated by advances in genomic analysis, that enable the measuring of genetic variation at a greater depth in a greater number of individuals and has led to a boom in genetic information. This has given us a greater understanding of the genetic aetiology of psychiatric disorders and how they are biologically related to each other. How this information can be translated to the clinics, can now be considered. Genetic testing in psychiatric disorders, is currently possible for certain disorders and mutation types, but is not universally advised. Much still remains to be understood about population level genetic risk factors before they could conceivably be utilised in the clinic. Whereas genetic testing of high impact mutations could be of use to the clinical programs, and are actively tested for in clinics across Europe.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.